{"groups":[{"description":"300 mg PO QD avapritinib: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.","id":"FG000","title":"Avapritinib"},{"description":"160 mg PO QD regorafenib: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).","id":"FG001","title":"Regorafinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"89"},{"groupId":"FG001","numSubjects":"87"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"32"}],"type":"Administrative/Other"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Not treated"},{"reasons":[{"groupId":"FG000","numSubjects":"91"},{"groupId":"FG001","numSubjects":"98"}],"type":"Sponsor decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"240"},{"groupId":"FG001","numSubjects":"236"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"240"},{"groupId":"FG001","numSubjects":"236"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}